Mark Barok: search on Z-Library

The world's largest scientific articles store. 70,000,000+ articles for free.

Don't use scam websites

1

Trastuzumab emtansine: mechanisms of action and drug resistance

Mark Barok,Heikki Joensuu,Jorma Isola

Journal:

Breast Cancer Research

Year:

2014

Language:

english

File:

PDF, 814 KB

english, 2014

2

Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells

Katri Köninki, Mark Barok, Minna Tanner, Synnöve Staff, Jukka Pitkänen, Päivikki Hemmilä, Joanna Ilvesaro, Jorma Isola

Journal:

Year:

2010

Language:

english

File:

PDF, 580 KB

english, 2010

3

EGFR gene copy number alterations in primary cutaneous malignant melanomas are associated with poor prognosis

Zsuzsa Rákosy, Laura Vízkeleti, Szilvia Ecsedi, Zoltán Vokó, Ágnes Bégány, Márk Barok, Zsuzsa Krekk, Mónika Gallai, Zoltán Szentirmay, Róza Ádány, Margit Balázs

Journal:

International Journal of Cancer

Year:

2007

Language:

english

File:

PDF, 306 KB

english, 2007

4

Die hard: Are cancer stem cells the Bruce Willises of tumor biology?

Ákos Fábián, Márk Barok, György Vereb, János Szöllősi

Journal:

Cytometry Part A

Year:

2009

Language:

english

File:

PDF, 202 KB

english, 2009

5

Optical coherence tomography detects structural abnormalities of the nasal mucosa in patients with cystic fibrosis

Oltmanns, Ute, Palmowski, Karin, Wielpütz, Mark, Kahn, Nicolas, Baroke, Eva, Eberhardt, Ralf, Wege, Sabine, Wiebel, Matthias, Kreuter, Michael, Herth, Felix J.F., Mall, Marcus A.

Journal:

Journal of Cystic Fibrosis

Year:

2015

Language:

english

File:

PDF, 617 KB

english, 2015

6

Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation

Barok, Mark, Puhka, Maija, Vereb, Gyorgy, Szollosi, Janos, Isola, Jorma, Joensuu, Heikki

Journal:

Year:

2018

Language:

english

File:

PDF, 4.52 MB

english, 2018

7

Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cellsin vivo

Mark Barok, Minna Tanner, Katri Köninki, Jorma Isola

Journal:

Breast Cancer Research

Year:

2011

Language:

english

File:

PDF, 1.88 MB

english, 2011

8

Steps in metastasis research: Analyzing, collecting, and culturing circulating tumor cells

Márk Barok, János Szöllősi

Journal:

Cytometry Part A

Year:

2011

Language:

english

File:

PDF, 67 KB

english, 2011

9

Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor

Márk Barok, Margit Balázs, Péter Nagy, Zsuzsa Rákosy, Andrea Treszl, Enikő Tóth, István Juhász, John W. Park, Jorma Isola, György Vereb, János Szöllősi

Journal:

Year:

2008

Language:

english

File:

PDF, 735 KB

english, 2008

10

Comparison of Antibodies for Immunohistochemistry-based Detection of HER3 in Breast Cancer

Luhtala, Satu, Staff, Synnöve, Barok, Mark, Tanner, Minna, Isola, Jorma

Journal:

Applied Immunohistochemistry & Molecular Morphology

Year:

2016

Language:

english

File:

PDF, 287 KB

english, 2016

11

A Novel Anti-HER2 Antibody-Drug Conjugate XMT-1522 for HER2-Positive Breast And Gastric Cancers Resistant to Trastuzumab Emtansine

Le Joncour, Vadim, Martins, Ana, Puhka, Maija, Isola, Jorma, Salmikangas, Marko, Laakkonen, Pirjo, Joensuu, Heikki, Barok, Mark

Journal:

Molecular Cancer Therapeutics

Year:

2019

Language:

english

File:

PDF, 2.64 MB

english, 2019

12

Corrigendum to “ErbB-directed immunotherapy: Antibodies in current practice and promising new agents” [Immunol. Lett. 116/2 (2008) 126–140]

Elza Friedländer, Márk Barok, János Szöllősi, György Vereb

Journal:

Immunology Letters

Year:

2009

Language:

english

File:

PDF, 105 KB

english, 2009

13

ErbB-directed immunotherapy: Antibodies in current practice and promising new agents

Elza Friedländer, Márk Barok, János Szöllősi, György Vereb

Journal:

Immunology Letters

Year:

2008

Language:

english

File:

PDF, 239 KB

english, 2008

14

ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer

Barok, Mark, Le Joncour, Vadim, Martins, Ana, Isola, Jorma, Salmikangas, Marko, Laakkonen, Pirjo, Joensuu, Heikki

Journal:

Year:

2020

File:

PDF, 3.10 MB

2020

15

Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer

Mark Barok, Minna Tanner, Katri Köninki, Jorma Isola

Journal:

Year:

2011

Language:

english

File:

PDF, 1.21 MB

english, 2011

16

Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer

Zsuzsanna Pályi-Krekk, Márk Barok, Jorma Isola, Markku Tammi, János Szöllo˝si, Peter Nagy

Journal:

European Journal of Cancer

Year:

2007

Language:

english

File:

PDF, 1.55 MB

english, 2007

17

EGFR and ErbB2 are functionally coupled to CD44 and regulate shedding, internalization and motogenic effect of CD44

Zsuzsanna Pályi-Krekk, Márk Barok, Tamás Kovács, Hideyuki Saya, Osamu Nagano, János Szöllősi, Peter Nagy

Journal:

Year:

2008

Language:

english

File:

PDF, 1012 KB

english, 2008

To build up a library is to create a life. It’s never just a random collection of books.

— Carlos María Domínguez

Official channel

Z-Library Desktop Launcher

Z-Library Since 2009 support@z-lib.do

EnglishРусскийEspañolItalianoελληνικάاللغة العربيةBahasa IndonesiaBahasa Malaysiaहिन्दीDeutschFrançaisPortuguêsУкраїнськаPolski中文繁體中文日本語Tiếng ViệtAzərbaycan DiliՀայոց լեզուภาษาไทยTürk Diliქართველიবাংলাپښتوతెలుగుاردو한국어SrpskiБългарски